Amneal Pharmaceuticals, Inc. Q3 FY2026 earnings call

• Strategic Integration: Closed the Kashif transaction in Q3, creating an end-to-end biosimilar platform combining Kashif’s R&D/manufacturing with Amneal’s commercial scale. Operations have fully resumed after flooding at an India facility in late July.
• Biosimilars Strategy: Focusing on first-or-second-to-market global opportunities. Pipeline includes Zolaire (expected H2 2027 launch) and Lanreotide (launched late Q3 with small initial contribution; targeting 30-40% market share long-term).
• Complex Generics & Innovations: Strong execution in complex therapies including inhalation (ProAir, QR approved; targeting five more MDI/soft mist approvals over next three years), ophthalmics (Iohexol full SKU portfolio filed), and sterile injectables (Landreotide, Respiradone).
• Specialty Growth: Trexon continues to gain Parkinson’s market share via clinical evidence. Brachia Autoinjector performance has doubled expectations for the year due to expanded access and high per-patient carton use.
• GLP-1 Partnership: Construction of dedicated manufacturing facilities for Pfizer collaboration remains on track for completion in late 2028/early 2029. Facilities are digitized and AI-enabled.
• Operational Resilience: Expanding capacity across 20 global facilities. Key expansions include women’s health patches, US-serine injectables by 2028, and biosimilar capacity in New Jersey and India.
• Financial Discipline: Prioritizing profitability over simple revenue growth, particularly in Upcare. Gross margins improved 50 bps YoY to 43.2% in Q3.

Revenue: $863 million (up 10% YoY). Adjusted EBITDA: $207 million (up 30% YoY). Adjusted EPS: $0.26 (up 53% YoY).

Affordable Medicines: Revenue of $547 million, up 19% YoY. This segment contributes approximately 63% of total revenue. Growth was driven by women’s health transdermal patches, new product launches adding $54 million, and timing benefits from a large biosimilar customer order.

Specialty: Revenue of $150 million, up 20% YoY. Contributes approximately 17% of total revenue. Growth is sustained by strong performance in Trexon (Parkinson’s), Raykia Autoinjector, and Unitroid.

Upcare: Revenue of $165 million, down 17% YoY. Contributes approximately 19% of total revenue. The decline is attributed to the non-repeating nature of a large product introduction in Q3 2025. On a comparable basis excluding this one-time event, revenue was stable while adjusted EBITDA grew double digits.

• Full Year 2026 Revenue Guidance: Increased by $50 million at the midpoint. New range: $3.15 billion to $3.25 billion.
• Full Year 2026 Adjusted EBITDA Guidance: Increased by $43 million at the midpoint. New range: $800 million to $815 million.
• Full Year 2026 Adjusted EPS Guidance: Increased by $5 cents at the midpoint. New range: $1.04 to $1.08.
• Full Year 2026 Operating Cash Flow Guidance: Decreased by $25 million at the midpoint. New range: $325 million to $375 million. The decrease reflects strategic increases in finished goods inventory to meet demand and timing shifts of collections to Q1 2027.
• Long-Term Outlook: Management expressed confidence in continued high growth into 2027 and beyond, driven by the base business expansion and a 'next wave' of launches between 2027-2029.

• Regulatory Approval Delays: Dependence on FDA approvals for key pipeline products like Landreotide strengths (60mg/90mg) and Zolaire patent settlement dates.
• Competitive Dynamics: Potential impact from competitors like Seltrion and Teva in the biosimilar space, specifically regarding Zolaire market entry.
• Supply Chain Disruptions: Past exposure to operational risks evidenced by flooding at an India facility, though currently resolved.
• Patent Settlement Uncertainty: Launch timelines for Zolaire remain contingent on finalizing patent settlement discussions with originators.
• Inventory Timing Risks: Strategic decision to build inventory impacts cash flow metrics in the short term, requiring careful management of working capital.

Q: Analyst asked for clarification on Lanreotide's Q3 revenue book and early metrics, plus status of 60mg/90mg strength filings.

A: CFO confirmed Lanreotide launched late Sept with ~$7M revenue, expecting significant growth in Q4. Targeting 30-40% long-term market share. Co-CEO stated post-approval supplements for 60mg/90mg strengths are ready for filing this quarter, with launches expected in H2 next year. Most cells are currently in the 120mg strength.

Q: Analyst asked about Zolaire launch timeline, competitive dynamics, and Brexia access dynamics.

A: Co-CEO noted Zolaire goal date is early next year, with active patent settlement discussions pushing launch to late H2 2027. Expect to be second to market behind Seltrion, with Teva also filed. EMA positive opinion expected late Nov. Regarding Brexia, seeing 50-60% conversion rates with minimal payer blocks initially; uptake is progressing well as awareness grows.

Q: Analyst asked about 2030 revenue mix (Affordable vs Specialty) and margin assumptions bridging to EPS.

A: CFO projected revenue growth from ~$3.1B to $4.3-4.5B by 2030, driven primarily by Affordable Medicines, specifically biosimilars from the Kashif acquisition. Margins are expected to improve further due to higher biosimilar gross margins, elimination of profit-sharing, and operational efficiencies/AI integration. Base business and complex generics also contribute to margin expansion.

Q: Analyst asked for updates on the Pfizer GLP-1 partnership and specialty brand guidance for Trexon/Brexia.

A: Co-CEO highlighted excellent progress with Pfizer; construction of AI-enabled facilities continues toward late 2028 completion. Amneal has exclusive access to 18 markets. Joe Renda (Specialty) reported Trexon adds ~400 new prescribers monthly, supporting confidence in higher-end long-term guidance. Brexia Autoinjector performance has already doubled annual expectations, with similar doubling anticipated for next year due to expanded distribution.